Current Size: 100%


Kaan Boztug wird der Clemens von Pirquet-Preis und der Österreichische Wissenschaftspreis für Kinder- und Jugendheilkunde 2018 verliehen

Kaan Boztug, Direktor des Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), zugehöriger Forschungsgruppenleiter am CeMM Zentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften und Professor für Kinder und Jugendheilkunde an der Medizinischen Universität Wien und am St. Anna Kinderspital, erhält für seine Forschung an seltenen Erkrankungen den diesjährigen Clemens von Pirquet-Preis.

LBI-RUD hosted a very succesful workshop on Human Phenotype Ontology (HPO)

From September 10-11, 2018 the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, in the person of Assoc. Prof. Kaan Boztug as Director of the LBI-RUD and head of ESID Working Party of Genetics, organized in cooperation with Marielle van Gijn (Head of Molecular Testing Working Group at ERN-RITA, a workshop on Human Phenotype Ontology (HPO) with a focus on immunodeficiencies and autoinflammatory diseases. HPO provides a standardized vocabulary to describe phenotypic (clinical) abnormalities observed in human diseases.

LBG Meeting for Health Sciences 2018

Call for Abstracts ends on September, 10th - Submit your abstract now

The Ludwig Boltzmann Gesellschaft invites interested scientists for this year’s LBG Meeting on Health Sciences from 29.-30. November 2018.
The meeting encourages and supports early career researchers to establish themselves within the scientific field. The conference focuses on the translation of research results from theory into practice. The thematic sessions will include keynote lectures by international experts and oral presentations of the best submitted abstracts.

WWTF Precision Medicine Grant for LBI-RUD Researchers

LBI-RUD director Kaan Boztug, together with Loïc Dupré (LBI-RUD) and Jörg Menche (CeMM) won one out of five prestigious research grants by the Vienna Science and Technology Fund (WWTF) in their 2016 Life Science Precision Medicine Call, granted for their innovative research project that has the potential to significantly contribute to major advancements in the field of personalized medicine and treatment options. The funding amounts to a total of nearly 1 Mio. EUR for three years.